{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:08:04Z","timestamp":1787692084252,"version":"build-2784847793"},"reference-count":174,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Thromboembolic disorders remain a primary cause of mortality globally, with their burden expected to increase due to an aging population. While various antithrombotic agents exist, many patients still rely on traditional gold-standard drugs like heparin, warfarin, and aspirin, which present significant drawbacks. These include the need for injections, frequent monitoring, dietary restrictions, drug interactions, bleeding complications, or other adverse reactions such as thrombocytopenia. In contrast, direct oral anticoagulants offer advantages over warfarin, including fewer interactions and less need for continuous monitoring. However, even with newer drugs, patients face risks of major bleeding events. Current research focuses on novel antithrombotic agents with superior efficacy and enhanced safety compared to existing treatments. Researchers are exploring specific clinical niches, such as factor XI\/XII inhibitors for cancer patients, to facilitate evaluation against standard treatments. The development of new antiplatelet drugs, like subcutaneous zalunfiban and selatogrel for pre-hospital therapy of myocardial infarction, and specific reversal agents, such as bentracimab for ticagrelor, exemplify this trend. Future research will likely focus on addressing the unmet needs of specific patient groups. This narrative review aimed to describe the current antithrombotic treatment and the most promising advances in the pharmacological management of thrombosis.<\/jats:p>","DOI":"10.3390\/ijms27073151","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:09:18Z","timestamp":1774944558000},"page":"3151","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological Management of Thrombosis: Current State and Future Strategies"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2406-5290","authenticated-orcid":false,"given":"Andrzej","family":"Mogielnicki","sequence":"first","affiliation":[{"name":"Department of Pharmacodynamics, Medical University of Bialystok, 15-089 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41573-020-0061-0","article-title":"Therapeutic Strategies for Thrombosis: New Targets and Approaches","volume":"19","author":"Mackman","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.7150\/thno.12494","article-title":"Blood Accessibility to Fibrin in Venous Thrombosis Is Thrombus Age-Dependent and Predicts Fibrinolytic Efficacy: An In Vivo Fibrin Molecular Imaging Study","volume":"5","author":"Kessinger","year":"2015","journal-title":"Theranostics"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17907","DOI":"10.1038\/s41598-018-35849-8","article-title":"Shape Changes of Erythrocytes during Blood Clot Contraction and the Structure of Polyhedrocytes","volume":"8","author":"Tutwiler","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/voxs.12331","article-title":"Role of Red Blood Cells in Haemostasis and Thrombosis","volume":"12","author":"Litvinov","year":"2017","journal-title":"ISBT Sci. Ser."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"072","DOI":"10.1055\/s-0033-1363470","article-title":"New Insights into the Role of Erythrocytes in Thrombus Formation","volume":"40","author":"Du","year":"2013","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00281-022-00916-w","article-title":"Mechanisms of Immunothrombosis and Vasculopathy in Antiphospholipid Syndrome","volume":"44","author":"Knight","year":"2022","journal-title":"Semin. Immunopathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/ATVBAHA.119.312463","article-title":"Neutrophil Extracellular Traps","volume":"39","author":"Hisada","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1152\/ajplegacy.1916.41.2.250","article-title":"The Thromboplastic Action of Cephalin","volume":"41","author":"McLean","year":"1916","journal-title":"Am. J. Physiol.-Leg. Content"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"10760296211052293","DOI":"10.1177\/10760296211052293","article-title":"General Considerations for Diversifying Heparin Drug Products by Improving the Current Heparin Manufacturing Process and Reintroducing Bovine Sourced Heparin to the US Market","volume":"27","year":"2021","journal-title":"Clin. Appl. Thromb."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/jcp.46.2.97","article-title":"The British Society for Haematology Guidelines on the Use and Monitoring of Heparin 1992: Second Revision. BCSH Haemostasis and Thrombosis Task Force","volume":"46","author":"Colvin","year":"1993","journal-title":"J. Clin. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"031","DOI":"10.1055\/s-2000-9497","article-title":"Comparative Pharmacokinetics of LMWHs","volume":"26","author":"Samama","year":"2000","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2016-11-709873","article-title":"Heparin-Induced Thrombocytopenia","volume":"129","author":"Arepally","year":"2017","journal-title":"Blood"},{"key":"ref_13","first-page":"321","article-title":"Management of Acute Coronary Syndromes with Fondaparinux","volume":"3","author":"Wienbergen","year":"2007","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism: Heparin-Induced Thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv."},{"key":"ref_16","first-page":"563","article-title":"Antithrombotic Effect of L-Arginine in Hypertensive Rats","volume":"55","author":"Cylwik","year":"2004","journal-title":"J. Physiol. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.chest.2022.07.025","article-title":"Perioperative Management of Antithrombotic Therapy","volume":"162","author":"Douketis","year":"2022","journal-title":"Chest"},{"key":"ref_18","first-page":"803","article-title":"Practical Suggestions for an Optimal Management of Vitamin K Antagonists: From Italian FCSA","volume":"124","author":"Galliazzo","year":"2024","journal-title":"TH Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/jcpt.13343","article-title":"A Review of Indications and Comorbidities in Which Warfarin May Be the Preferred Oral Anticoagulant","volume":"46","author":"Wadsworth","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_20","first-page":"4","article-title":"Pharmacogenetic Considerations of Anticoagulant Medication","volume":"69","author":"Miklosz","year":"2018","journal-title":"J. Physiol. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update","volume":"102","author":"Johnson","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa044503","article-title":"Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose","volume":"352","author":"Rieder","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2217\/14622416.9.10.1445","article-title":"VKORC1 Polymorphisms, Haplotypes and Haplotype Groups on Warfarin Dose among African-Americans and European-Americans","volume":"9","author":"Limdi","year":"2008","journal-title":"Pharmacogenomics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jama.293.6.736","article-title":"Ximelagatran\u2014Promises and Concerns","volume":"293","author":"Gurewich","year":"2005","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1756-8722-4-53","article-title":"Pharmacological Basis and Clinical Evidence of Dabigatran Therapy","volume":"4","author":"Redondo","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The Pharmacokinetics, Pharmacodynamics and Tolerability of Dabigatran Etexilate, a New Oral Direct Thrombin Inhibitor, in Healthy Male Subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2019.02.080","article-title":"Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3\/5)","volume":"74","author":"Verheugt","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet Lond. Engl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12325-022-02333-9","article-title":"Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: A Narrative Review","volume":"40","author":"Ballestri","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_31","first-page":"j5058","article-title":"Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis","volume":"359","author":"Sterne","year":"2017","journal-title":"BMJ"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI108132","article-title":"The Mechanism of the Effect of Aspirin on Human Platelets. I. Acetylation of a Particulate Fraction Protein","volume":"56","author":"Roth","year":"1975","journal-title":"J. Clin. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1161\/CIRCULATIONAHA.110.963843","article-title":"Aspirin: A Historical and Contemporary Therapeutic Overview","volume":"123","author":"Fuster","year":"2011","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"CURRENT-OASIS 7 Investigators, Mehta, S.R., Bassand, J.-P., Chrolavicius, S., Diaz, R., Eikelboom, J.W., Fox, K.A.A., Granger, C.B., Jolly, S., and Joyner, C.D. (2010). Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. N. Engl. J. Med., 363, 930\u2013942.","DOI":"10.1056\/NEJMoa0909475"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"10760296241244772","DOI":"10.1177\/10760296241244772","article-title":"Efficacy and Safety of Long-Term Dual Antiplatelet Therapy: A Systematic Review and Meta-Analysis","volume":"30","author":"Zhang","year":"2024","journal-title":"Clin. Appl. Thromb."},{"key":"ref_38","unstructured":"Topaz, O. (2018). Chapter 4\u2014The Role of Platelets in the Pathophysiology of Atherosclerosis and Its Complications. Cardiovascular Thrombus, Academic Press."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1016\/j.jtha.2023.09.013","article-title":"Antiplatelet Strategies: Past, Present, and Future","volume":"21","author":"Stanger","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Zhang, Y.-J., Li, M.-P., Tang, J., and Chen, X.-P. (2017). Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidence and Perspectives. Int. J. Environ. Res. Public Health, 14.","DOI":"10.3390\/ijerph14030301"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","article-title":"Identification and Biological Activity of the Active Metabolite of Clopidogrel","volume":"84","author":"Savi","year":"2000","journal-title":"Thromb. Haemost."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of Clopidogrel to Aspirin in 45,852 Patients with Acute Myocardial Infarction: Randomised Placebo-Controlled Trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet Lond. Engl."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1477-9560-9-4","article-title":"The Influence of CYP 2C19*2 Polymorphism on Platelet Function Testing during Single Antiplatelet Treatment with Clopidogrel","volume":"9","author":"Pettersen","year":"2011","journal-title":"Thromb. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41569-023-00854-6","article-title":"Current Concepts and Novel Targets for Antiplatelet Therapy","volume":"20","author":"Gawaz","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_47","unstructured":"European Medicines Agency (2026, March 18). Efient, INN-Prasugrel: Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/efient-epar-product-information_en.pdf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/11630960-000000000-00000","article-title":"Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile of the Oral Antiplatelet Agent Ticagrelor","volume":"51","author":"Teng","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Lofrumento, F., Irrera, N., Licordari, R., Perfetti, S., Nasso, E., Liotta, P., Isgr\u00f2, G., Garcia-Ruiz, V., Squadrito, F., and Di Bella, G. (2023). Off-Target Effects of P2Y12 Receptor Inhibitors: Focus on Early Myocardial Fibrosis Modulation. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242417546"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/1074248411410883","article-title":"Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Induced Hyperemia Responses","volume":"17","author":"Sidaway","year":"2012","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5603\/cj.96076","article-title":"Cangrelor\u2014Expanding Therapeutic Options in Patients with Acute Coronary Syndrome","volume":"31","author":"Kubica","year":"2024","journal-title":"Cardiol. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.carrev.2016.10.005","article-title":"A Comparison of Cangrelor, Prasugrel, Ticagrelor, and Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Network Meta-Analysis","volume":"18","author":"Westman","year":"2017","journal-title":"Cardiovasc. Revasc. Med. Mol. Interv."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"EPIC Investigators (1994). Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb\/IIIa Receptor in High-Risk Coronary Angioplasty. N. Engl. J. Med., 330, 956\u2013961.","DOI":"10.1056\/NEJM199404073301402"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1055\/s-0037-1616241","article-title":"Anti-GPIIb\/IIIa Drugs: Current Strategies and Future Directions","volume":"86","author":"Coller","year":"2001","journal-title":"Thromb. Haemost."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e031855","DOI":"10.1161\/JAHA.123.031855","article-title":"Critical Analysis of Thrombocytopenia Associated with Glycoprotein IIb\/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s)","volume":"12","author":"Rikken","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"ref_58","unstructured":"CSL Behring Canada, Inc. (2026, March 18). Streptase\u00ae (Streptokinase Injection): Product Monograph. Available online: https:\/\/pdf.hres.ca\/dpd_pm\/00003639.PDF."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jama.1996.03540120039031","article-title":"Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase Trial (ASK) Study Group","volume":"276","author":"Donnan","year":"1996","journal-title":"JAMA"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"(1995). Multicentre Acute Stroke Trial\u2014Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet, 346, 1509\u20131514.","DOI":"10.1016\/S0140-6736(95)92049-8"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Teng, R.S.Y. (2024). The Future of Fibrinolysis Agents, IntechOpen.","DOI":"10.5772\/intechopen.115012"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11936-022-00973-2","article-title":"Intravenous Thrombolytics in the Treatment of Acute Ischemic Stroke","volume":"25","author":"Alhadid","year":"2023","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2165\/11209940-000000000-00000","article-title":"Alteplase","volume":"26","author":"Dhillon","year":"2012","journal-title":"CNS Drugs"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/00129784-200606040-00007","article-title":"Reteplase","volume":"6","author":"Simpson","year":"2006","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2165\/00003088-200241150-00001","article-title":"Pharmacokinetics and Pharmacodynamics of Tenecteplase in Fibrinolytic Therapy of Acute Myocardial Infarction","volume":"41","author":"Tanswell","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"17562864231221324","DOI":"10.1177\/17562864231221324","article-title":"Tenecteplase for the Treatment of Acute Ischemic Stroke in the Extended Time Window: A Systematic Review and Meta-Analysis","volume":"17","author":"Palaiodimou","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_67","unstructured":"(2026, March 20). Genentech: Press Releases|Monday, 3 March 2025. Available online: https:\/\/www.gene.com\/media\/press-releases\/15053\/2025-03-03\/fda-approves-genentechs-tnkase-in-acute-."},{"key":"ref_68","unstructured":"Prabhakaran, S., Gonzalez, N.R., Zachrison, K.S., Adeoye, O., Alexandrov, A.W., Ansari, S.A., Chapman, S., Czap, A.L., Dumitrascu, O.M., and Ishida, K. (Stroke, 2026). 2026 Guideline for the Early Management of Patients with Acute Ischemic Stroke: A Guideline from the American Heart Association\/American Stroke Association, Stroke, in press."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1111\/bcp.14608","article-title":"Warfarin Dosing Algorithms: A Systematic Review","volume":"87","author":"Asiimwe","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A Novel User-Friendly Score (HAS-BLED) to Assess 1-Year Risk of Major Bleeding in Patients with Atrial Fibrillation: The Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1160\/TH16-10-0810","article-title":"External Validation of the VTE-BLEED Score for Predicting Major Bleeding in Stable Anticoagulated Patients with Venous Thromboembolism","volume":"117","author":"Klok","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A New Risk Scheme to Predict Warfarin-Associated Hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study","volume":"58","author":"Fang","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical Classification Schemes for Predicting Hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am. Heart J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ahj.2011.07.001","article-title":"Outcomes Registry for Better Informed Treatment of Atrial Fibrillation: Rationale and Design of ORBIT-AF","volume":"162","author":"Piccini","year":"2011","journal-title":"Am. Heart J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Rienstra","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12959-023-00501-7","article-title":"The Methods for Removal of Direct Oral Anticoagulants and Heparins to Improve the Monitoring of Hemostasis: A Narrative Literature Review","volume":"21","author":"Frackiewicz","year":"2023","journal-title":"Thromb. J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: A consensus document from the Academic Research Consortium for High Bleeding Risk","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary Thrombosis and Major Bleeding After PCI with Drug-Eluting Stents: Risk Scores from PARIS","volume":"67","author":"Baber","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2217\/14796678.4.1.33","article-title":"Monitoring Antiplatelet Therapy with Point-of-Care Platelet Function Assays: A Review of the Evidence","volume":"4","author":"Hackeng","year":"2008","journal-title":"Future Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1055\/s-0035-1570083","article-title":"Platelet Function Testing in Patients on Antiplatelet Medications","volume":"42","author":"Gross","year":"2016","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_84","first-page":"1","article-title":"Antiplatelet Drug Response Variability and the Role of Platelet Function Testing: A Practical Guide for Interventional Cardiologists","volume":"73","author":"Angiolillo","year":"2009","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Kuliczkowski, W., Witkowski, A., Watala, C., Filipiak, K.J., Budaj, A., Golanski, J., Sitkiewicz, D., Pregowski, J., Gorski, J., and Zembala, M. (2008). Resistance to Oral Antiplatelet Drugs--a Position Paper of the Working Group on Antiplatelet Drug Resistance Appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society. Kardiol. Pol., 66.","DOI":"10.1093\/eurheartj\/ehn562"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and Stent Thrombosis on P2Y12-Inhibitors: Collaborative Analysis on the Role of Platelet Reactivity for Risk Stratification after Percutaneous Coronary Intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/1358863X221115213","article-title":"Risk of Nonmajor Bleeding upon Use of Direct Oral Anticoagulants for Preventing and Treating Venous Thromboembolism: A Network Meta-Analysis","volume":"27","author":"Chen","year":"2022","journal-title":"Vasc. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1182\/bloodadvances.2019000572","article-title":"Systematic Review and Meta-Analysis of the Efficacy and Safety of Apixaban Compared to Rivaroxaban in Acute VTE in the Real World","volume":"3","author":"Aryal","year":"2019","journal-title":"Blood Adv."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"ehac544.624","DOI":"10.1093\/eurheartj\/ehac544.624","article-title":"Incidence and Risk Factors for Major Bleeding Events in Atrial Fibrillation Patients on Direct Oral Anticoagulant Therapy: Data from the National Patient-Centered Clinical Research Network","volume":"43","author":"Arps","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_91","first-page":"246","article-title":"Analysis of Upper Gastrointestinal Adverse Events among Patients given Dabigatran in the RE-LY Trial","volume":"11","author":"Bytzer","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/bmj.321.7270.1183","article-title":"Risk of Gastrointestinal Haemorrhage with Long Term Use of Aspirin: Meta-Analysis","volume":"321","author":"Derry","year":"2000","journal-title":"BMJ"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1182\/blood.2020009300","article-title":"Genetics of Inherited Thrombocytopenias","volume":"139","author":"Warren","year":"2022","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/asheducation-2018.1.576","article-title":"Drug-Associated Thrombocytopenia","volume":"2018","author":"Bakchoul","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"100283","DOI":"10.1016\/j.rpth.2023.100283","article-title":"Heparin-Induced Thrombocytopenia: An Illustrated Review","volume":"7","author":"May","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/jth.12052","article-title":"A Systematic Evaluation of Laboratory Testing for Drug-Induced Immune Thrombocytopenia","volume":"11","author":"Arnold","year":"2013","journal-title":"J. Thromb. Haemost. JTH"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3324\/haematol.2021.279484","article-title":"Treatment of Drug-Induced Immune Thrombocytopenias","volume":"107","author":"Marini","year":"2022","journal-title":"Haematologica"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1055\/s-0032-1325615","article-title":"Nonhemostatic Adverse Effects of Anticoagulants and Antiplatelet Agents","volume":"38","author":"Walenga","year":"2012","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.chest.2024.03.003","article-title":"Antithrombotic Therapy for VTE Disease: Compendium and Review of CHEST Guidelines 2012\u20132021","volume":"166","author":"Stevens","year":"2024","journal-title":"Chest"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1161\/CIR.0000000000001257","article-title":"CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement from the American Heart Association","volume":"150","author":"Pereira","year":"2024","journal-title":"Circulation"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Makam, R.C.P., Hoaglin, D.C., McManus, D.D., Wang, V., Gore, J.M., Spencer, F.A., Pradhan, R., Tran, H., Yu, H., and Goldberg, R.J. (2018). Efficacy and Safety of Direct Oral Anticoagulants Approved for Cardiovascular Indications: Systematic Review and Meta-Analysis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0197583"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_105","first-page":"CD006650","article-title":"Anticoagulation for the Long-Term Treatment of Venous Thromboembolism in People with Cancer","volume":"6","author":"Kahale","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ejvs.2018.11.004","article-title":"Editor\u2019s Choice\u2014A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer","volume":"57","author":"Kirkilesis","year":"2019","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral Factor Xa Inhibitor with Low Molecular Weight Heparin in Patients with Cancer with Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood.2019000919","article-title":"Novel Antithrombotic Strategies for Treatment of Venous Thromboembolism","volume":"135","author":"Weitz","year":"2020","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"FXI-ASO TKA Investigators Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis","volume":"372","author":"Bethune","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a Novel FXI Antibody with a Unique Binding Mode, Shows Durable Effects on Markers of Anticoagulation in Humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and Pharmacodynamics of Abelacimab (MAA868), a Novel Dual Inhibitor of Factor XI and Factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J. Thromb. Haemost. JTH"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41591-023-02794-7","article-title":"Anticoagulation with Osocimab in Patients with Kidney Failure Undergoing Hemodialysis: A Randomized Phase 2 Trial","volume":"30","author":"Weitz","year":"2024","journal-title":"Nat. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological Profile of Asundexian, a Novel, Orally Bioavailable Inhibitor of Factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the Oral Factor XIa Inhibitor Asundexian Compared with Apixaban in Patients with Atrial Fibrillation (PACIFIC-AF): A Multicentre, Randomised, Double-Blind, Double-Dummy, Dose-Finding Phase 2 Study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet Lond. Engl."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"117436","DOI":"10.1016\/j.ejmech.2025.117436","article-title":"Discovery of Potent, Highly Selective, and Orally Bioavailable Factor XIa Inhibitors for Anticoagulant Therapy","volume":"289","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1021\/acs.biomac.9b01688","article-title":"Anticoagulant Heparin Mimetics via RAFT Polymerization","volume":"21","author":"Nahain","year":"2020","journal-title":"Biomacromolecules"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2402191","DOI":"10.1002\/adhm.202402191","article-title":"Synthesis, Biological Evaluation and Reversal of Sulfonated Di- and Triblock Copolymers as Novel Parenteral Anticoagulants","volume":"13","author":"Swieton","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"112452","DOI":"10.1016\/j.eurpolymj.2023.112452","article-title":"Anionic and Cationic Block Copolymers as Promising Modulators of Blood Coagulation","volume":"199","author":"Swieton","year":"2023","journal-title":"Eur. Polym. J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood-2014-05-577932","article-title":"Nontoxic Polyphosphate Inhibitors Reduce Thrombosis While Sparing Hemostasis","volume":"124","author":"Travers","year":"2014","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/s41467-023-37709-0","article-title":"Smart Thrombosis Inhibitors without Bleeding Side Effects via Charge Tunable Ligand Design","volume":"14","author":"La","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ahj.2023.04.009","article-title":"Prepercutaneous Coronary Intervention Zalunfiban Dose-Response Relationship to Target Vessel Blood Flow at Initial Angiogram in St-Elevation Myocardial Infarction\u2014A Post Hoc Analysis of the Cel-02 Phase IIa Study","volume":"262","author":"Rikken","year":"2023","journal-title":"Am. Heart J."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1016\/j.jacc.2020.03.059","article-title":"Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients with Acute Myocardial Infarction","volume":"75","author":"Sinnaeve","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/phar.2620","article-title":"Safety and Efficacy of a Platelet Glycoprotein Ib Inhibitor for Patients with Non-ST Segment Elevation Myocardial Infarction: A Phase Ib\/IIa Study","volume":"41","author":"Zheng","year":"2021","journal-title":"Pharmacotherapy"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"100025","DOI":"10.1016\/j.brci.2025.100025","article-title":"Crizanlizumab and Inclacumab Are Equally Potent Inhibitors of Cell Adhesion in the Blood of Patients with Sickle Cell Disease","volume":"1","author":"Kaminski","year":"2025","journal-title":"Blood Red Cells Iron"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/jamacardio.2021.0475","article-title":"Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-Blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial","volume":"6","author":"Mayer","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(23)00427-1","article-title":"Safety and Efficacy of Platelet Glycoprotein VI Inhibition in Acute Ischaemic Stroke (ACTIMIS): A Randomised, Double-Blind, Placebo-Controlled, Phase 1b\/2a Trial","volume":"23","author":"Mazighi","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1124\/jpet.121.000973","article-title":"ML355 Modulates Platelet Activation and Prevents ABT-737 Induced Apoptosis in Platelets","volume":"381","author":"Shpakova","year":"2022","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e125851","DOI":"10.1172\/jci.insight.125851","article-title":"Targeting Protein Disulfide Isomerase with the Flavonoid Isoquercetin to Improve Hypercoagulability in Advanced Cancer","volume":"4","author":"Zwicker","year":"2019","journal-title":"JCI Insight"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1053\/euhj.2000.2498","article-title":"Intravenous NPA for the Treatment of Infarcting Myocardium Early: InTIME-II, a Double-Blind Comparison of Single-Bolus Lanoteplase vs Accelerated Alteplase for the Treatment of Patients with Acute Myocardial Infarction","volume":"21","author":"Braunwald","year":"2000","journal-title":"Eur. Heart J."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40261-021-01112-8","article-title":"Safety, Pharmacokinetics and Pharmacodynamics of DS-1040, in Combination with Thrombectomy, in Japanese Patients with Acute Ischemic Stroke","volume":"42","author":"Sakai","year":"2022","journal-title":"Clin. Drug Investig."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s12028-014-9972-0","article-title":"Reversal of Coagulopathy Using Prothrombin Complex Concentrates Is Associated with Improved Outcome Compared to Fresh Frozen Plasma in Warfarin-Associated Intracranial Hemorrhage","volume":"21","author":"Frontera","year":"2014","journal-title":"Neurocrit. Care"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s40001-024-01816-5","article-title":"Reversal and Resumption of Anticoagulants in Patients with Anticoagulant-Associated Intracerebral Hemorrhage","volume":"29","author":"Yang","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/17425255.2016.1194395","article-title":"The Toxicology of Heparin Reversal with Protamine: Past, Present and Future","volume":"12","author":"Sokolowska","year":"2016","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Miklosz, J., Kalaska, B., Podlasz, P., Chmielewska-Krzesi\u0144ska, M., Zaj\u0105czkowski, M., Kosi\u0144ski, A., Pawlak, D., and Mogielnicki, A. (2021). Cardiovascular and Respiratory Toxicity of Protamine Sulfate in Zebrafish and Rodent Models. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13030359"},{"key":"ref_139","first-page":"886","article-title":"Cardiac Arrest Following Protamine Administration: A Case Series","volume":"21","author":"Leung","year":"2019","journal-title":"EP Eur."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Miklosz, J., Kalaska, B., Kaminski, K., Rusak, M., Szczubialka, K., Nowakowska, M., Pawlak, D., and Mogielnicki, A. (2019). The Inhibitory Effect of Protamine on Platelets Is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents. Mar. Drugs, 17.","DOI":"10.3390\/md17090539"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Kalaska, B., Kaminski, K., Sokolowska, E., Czaplicki, D., Kujdowicz, M., Stalinska, K., Bereta, J., Szczubialka, K., Pawlak, D., and Nowakowska, M. (2015). Nonclinical Evaluation of Novel Cationically Modified Polysaccharide Antidotes for Unfractionated Heparin. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0119486"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.trsl.2016.06.009","article-title":"Heparin-Binding Copolymer Reverses Effects of Unfractionated Heparin, Enoxaparin, and Fondaparinux in Rats and Mice","volume":"177","author":"Kalaska","year":"2016","journal-title":"Transl. Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1124\/jpet.119.262931","article-title":"Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats","volume":"373","author":"Kalaska","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Swieton, J., Miklosz, J., Yusa, S.-I., Szczubialka, K., Pawlak, D., Mogielnicki, A., and Kalaska, B. (2021). Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222011149"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.thromres.2016.07.008","article-title":"Ciraparantag Safely and Completely Reverses the Anticoagulant Effects of Low Molecular Weight Heparin","volume":"146","author":"Ansell","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/eurheartj\/ehab637","article-title":"Ciraparantag Reverses the Anticoagulant Activity of Apixaban and Rivaroxaban in Healthy Elderly Subjects","volume":"43","author":"Ansell","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"260ra150","DOI":"10.1126\/scitranslmed.3009427","article-title":"Affinity-Based Design of a Synthetic Universal Reversal Agent for Heparin Anticoagulants","volume":"6","author":"Shenoi","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1021\/acs.biomac.7b00994","article-title":"A Polymer Therapeutic Having Universal Heparin Reversal Activity: Molecular Design and Functional Mechanism","volume":"18","author":"Kalathottukaren","year":"2017","journal-title":"Biomacromolecules"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e211693","DOI":"10.1001\/jamahealthforum.2021.1693","article-title":"National Trends in Use of and Spending on Oral Anticoagulants Among US Medicare Beneficiaries from 2011 to 2019","volume":"2","author":"Troy","year":"2021","journal-title":"JAMA Health Forum"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jtha.2024.07.009","article-title":"Reversal of Direct Oral Anticoagulants: Guidance from the SSC of the ISTH","volume":"22","author":"Levy","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final Study Report of Andexanet Alfa for Major Bleeding with Factor Xa Inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for Factor Xa Inhibitor\u2013Associated Acute Intracerebral Hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_153","unstructured":"U.S. Food and Drug Administration (2026, March 19). Update on the Safety of Andexxa, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/update-safety-andexxa."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/EJA.0000000000001968","article-title":"Clinical Guideline on Reversal of Direct Oral Anticoagulants in Patients with Life Threatening Bleeding","volume":"41","author":"Grottke","year":"2024","journal-title":"Eur. J. Anaesthesiol. EJA"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/eurheartj\/ehad123","article-title":"Reversal Agents for Current and Forthcoming Direct Oral Anticoagulants","volume":"44","author":"Weitz","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/STROKEAHA.120.029789","article-title":"Phase 1b Study to Evaluate Safety, Tolerability, and Maximum Tolerated Dose of PF-05230907 for Intracerebral Hemorrhage","volume":"52","author":"Diringer","year":"2021","journal-title":"Stroke"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1021\/acs.nanolett.2c02019","article-title":"Locking and Unlocking Thrombin Function Using Immunoquiescent Nucleic Acid Nanoparticles with Regulated Retention In Vivo","volume":"22","author":"Ke","year":"2022","journal-title":"Nano Lett."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1021\/acs.jmedchem.1c02054","article-title":"Dynamic Combinatorial Optimization of In Vitro and In Vivo Heparin Antidotes","volume":"65","author":"Carbajo","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e2400108","DOI":"10.1002\/adhm.202400108","article-title":"External Trigger Free Charge Switchable Cationic Ligands in the Design of Safe and Effective Universal Heparin Antidote","volume":"13","author":"La","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.thromres.2023.05.003","article-title":"OKL-1111, A Modified Cyclodextrin as a Potential Universal Reversal Agent for Anticoagulants","volume":"227","author":"Meijers","year":"2023","journal-title":"Thromb. Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0140-6736(15)00515-2","article-title":"Effect of the REG1 Anticoagulation System versus Bivalirudin on Outcomes after Percutaneous Coronary Intervention (REGULATE-PCI): A Randomised Clinical Trial","volume":"387","author":"Lincoff","year":"2016","journal-title":"Lancet"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41587-024-02209-z","article-title":"Development of Supramolecular Anticoagulants with On-Demand Reversibility","volume":"43","author":"Dockerill","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1021\/acs.biomac.8b00691","article-title":"Anticoagulant Properties of Poly(Sodium 2-(Acrylamido)-2-Methylpropanesulfonate)-Based Di- and Triblock Polymers","volume":"19","author":"Kalaska","year":"2018","journal-title":"Biomacromolecules"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease Developed in Collaboration with EACTS: The Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1055\/s-0039-1693738","article-title":"Antagonizing P2Y12 Receptor Inhibitors: Current and Future Options","volume":"119","author":"Trenk","year":"2019","journal-title":"Thromb. Haemost."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa1901778","article-title":"Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1111\/trf.15219","article-title":"Reversal of the Antiplatelet Effect of Ticagrelor by Simulated Platelet Transfusion","volume":"59","author":"Zhang","year":"2019","journal-title":"Transfusion"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/psp4.12734","article-title":"Population Pharmacokinetic-Pharmacodynamic Modeling of PB2452, a Monoclonal Antibody Fragment Being Developed as a Ticagrelor Reversal Agent, in Healthy Volunteers","volume":"11","author":"Kathman","year":"2022","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"EVIDoa2100047","DOI":"10.1056\/EVIDoa2100047","article-title":"Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery","volume":"1","author":"Bhatt","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jacc.2021.07.048","article-title":"Intracranial Hemorrhage During Dual Antiplatelet Therapy","volume":"78","author":"Ha","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/jclinpath-2016-204117","article-title":"Ticagrelor Reversal: In Vitro Assessment of Four Haemostatic Agents","volume":"70","author":"Calmette","year":"2017","journal-title":"J. Clin. Pathol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jacbts.2017.01.007","article-title":"Ticagrelor Removal from Human Blood","volume":"2","author":"Angheloiu","year":"2017","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.athoracsur.2018.12.032","article-title":"Cytosorb Adsorption During Emergency Cardiac Operations in Patients at High Risk of Bleeding","volume":"108","author":"Hassan","year":"2019","journal-title":"Ann. Thorac. Surg."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse Impact of Bleeding on Prognosis in Patients with Acute Coronary Syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/3151\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T04:19:21Z","timestamp":1775189961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/3151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":174,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ijms27073151"],"URL":"https:\/\/doi.org\/10.3390\/ijms27073151","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]}}}